18. The use of claim 17, wherein said scarring derives from a wound, a burn, a scar, wrinkles, stretch marks, sun damage, chemical damage, heat damage, cold damage, a trauma, a surgical injury, a radiation or an ulcer.

19. The method of claim 18, wherein said ulcer is diabetic foot ulcer, venous leg ulcer or pressure ulcer.

20. The use according to any one of claims 1-4, wherein the fibrotic disease is cardiac fibrosis.

21. The use of claim 20, wherein the cardiac fibrosis is cardiomyopathy, congestive heart failure.

22. Use of a therapeutically effective amount of a compound as defined in any one of claims 1-4, in the manufacture of a medicament for antagonizing collagen secretion or collagen deposition in an organ of a mammal, wherein the organ is lung, liver, skin or heart.


23. Use of a therapeutically effective amount of a compound as defined in any one of claims 1-4 in the manufacture of a medicament for reducing the collagen production in cells, wherein said compound is to be contacted with the cells.

24. The use according to any one of claims 1-21, wherein the compound is to be administered in combination with a therapeutically effective amount of second compound, the second compound is an immunosuppressive drug, an anti-inflammatory drug, a cytokine, a monoclonal antibody, a multiple receptor tyrosine kinase inhibitor, an antioxidant, an enzyme inhibitor, an integrin inhibitor, a lipid receptor modulator or a thiazolindione.

25. The use according to claim 24, wherein the fibrotic disease is pulmonary fibrosis, and wherein the compound is administered in combination with a therapeutically effective amount of pirfenidone.

26. The use according to any one of claims 5 to 8, wherein the compound is to be administered in combination with a therapeutically effective amount of nintedanib.

27. A compound represented by the formula:



or a pharmaceutically acceptable salt thereof, wherein

A is C_5 alkyl, C_6 alkyl, C_5 alkenyl, C_6 alkenyl, $C(O)-(CH_2)_n-CH_3$ or $CH(OH)-(CH_2)_n-CH_3$ wherein n is 3 or 4;

R_1 is H, OH or F;

R_2 is H, OH, F or CH_2-OH;

R_3 is CH_2Ph;

R_4 is H, OH or F;

Q is

1) $(CH_2)_mC(O)OH$ wherein m is 1 or 2,

2) $CH(CH_3)C(O)OH$,

3) $C(CH_3)_2C(O)OH$,

4) CH(F)-C(O)OH,

5) CF_2-C(O)OH, or

6) C(O)-C(O)OH.

28. The compound of claim 27, wherein the compound is:

Compound XX	